Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB019 in Healthy Subjects and Psoriasis Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Imsidolimab (Primary) ; Imsidolimab (Primary)
- Indications Plaque psoriasis; Pustular psoriasis
- Focus Adverse reactions; First in man
- Sponsors AnaptysBio
- 14 Nov 2018 Status changed from active, no longer recruiting to completed.
- 29 May 2018 Results presented in an AnaptysBio media release.
- 29 May 2018 According to an AnaptysBio media release, clinical data from this study was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018.